Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Peter Gasser, Katharina Kirchner, Torsten Passie
Journal of Psychopharmacology (2014) Vol. 29, Iss. 1, pp. 57-68
Closed Access | Times Cited: 400

Showing 26-50 of 400 citing articles:

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Friederike Holze, Patrick Vizeli, Felix Müller, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 3, pp. 462-471
Open Access | Times Cited: 187
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews
Rafael G. dos Santos, José Carlos Bouso, Miguel Ángel Alcázar‐Córcoles, et al.
Expert Review of Clinical Pharmacology (2018) Vol. 11, Iss. 9, pp. 889-902
Closed Access | Times Cited: 186
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Danilo De Gregorio, Argel Aguilar‐Valles, Katrin H. Preller, et al.
Journal of Neuroscience (2020) Vol. 41, Iss. 5, pp. 891-900
Open Access | Times Cited: 185
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti, Patrick C. Dolder, Yasmin Schmid
Psychopharmacology (2016) Vol. 234, Iss. 9-10, pp. 1499-1510
Open Access | Times Cited: 184
Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature
Timothy I. Michaels, Jennifer Purdon, Alexis Collins, et al.
BMC Psychiatry (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 184
Long-term effects of psychedelic drugs: A systematic review
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 179-189
Closed Access | Times Cited: 184
Ayahuasca: Pharmacology, neuroscience and therapeutic potential
Elisabet Domínguez‐Clavé, Joaquim Soler, Matilde Elices, et al.
Brain Research Bulletin (2016) Vol. 126, pp. 89-101
Closed Access | Times Cited: 181
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Leor Roseman, Lysia Demetriou, Matthew B. Wall, et al.
Neuropharmacology (2017) Vol. 142, pp. 263-269
Open Access | Times Cited: 180
Towards an understanding of psychedelic-induced neuroplasticity
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 104-112
Open Access | Times Cited: 177
A systematic study of microdosing psychedelics
Vince Polito, Richard J. Stevenson
PLoS ONE (2019) Vol. 14, Iss. 2, pp. e0211023-e0211023
Open Access | Times Cited: 176
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
Anat Levit, Danielle N. Confair, Kuglae Kim, et al.
Nature (2022) Vol. 610, Iss. 7932, pp. 582-591
Open Access | Times Cited: 176
Clinical applications of hallucinogens: A review.
Albert Garcia‐Romeu, Brennan Kersgaard, Peter H. Addy
Experimental and Clinical Psychopharmacology (2016) Vol. 24, Iss. 4, pp. 229-268
Open Access | Times Cited: 175
Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Friederike Holze, Peter Gasser, Felix Müller, et al.
Biological Psychiatry (2022) Vol. 93, Iss. 3, pp. 215-223
Closed Access | Times Cited: 170
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 166
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion
Jamilah R. George, Timothy I. Michaels, Jae Sevelius, et al.
Journal of Psychedelic Studies (2019) Vol. 4, Iss. 1, pp. 4-15
Open Access | Times Cited: 157
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Friederike Holze, Laura Ley, Felix Müller, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 6, pp. 1180-1187
Open Access | Times Cited: 148
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Roberta Murphy, Hannes Kettner, Rick Zeifman, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 143
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Max Wolff, Ricarda Evens, Lea J. Mertens, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 140
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Alan K. Davis, Frederick S. Barrett, Sara So, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 437-446
Open Access | Times Cited: 129
Psychedelics alter metaphysical beliefs
Christopher Timmermann, Hannes Kettner, Chris Letheby, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 128
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1100-1117
Open Access | Times Cited: 127
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Nicole Leite Galvão‐Coelho, Wolfgang Marx, Maria Gonzalez, et al.
Psychopharmacology (2021) Vol. 238, Iss. 2, pp. 341-354
Open Access | Times Cited: 119
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review
Nina Schimmers, Joost J. Breeksema, Sanne Y. Smith-Apeldoorn, et al.
Psychopharmacology (2021) Vol. 239, Iss. 1, pp. 15-33
Closed Access | Times Cited: 111
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102

Scroll to top